ORCHESTRA BIOMED HOLDINGS IN (OBIO)
US68572M1062 - Common Stock
Overall OBIO gets a fundamental rating of 3 out of 10. We evaluated OBIO against 187 industry peers in the Health Care Equipment & Supplies industry. While OBIO seems to be doing ok healthwise, there are quite some concerns on its profitability. OBIO is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year OBIO has reported negative net income.
In the past year OBIO has reported a negative cash flow from operations.
1.2 Ratios
OBIO's Return On Assets of -76.79% is on the low side compared to the rest of the industry. OBIO is outperformed by 79.68% of its industry peers.
OBIO's Return On Equity of -125.96% is on the low side compared to the rest of the industry. OBIO is outperformed by 72.19% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -76.79% | ||
| ROE | -125.96% | ||
| ROIC | N/A |
ROA(3y)-86.31%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
OBIO has a better Gross Margin (92.07%) than 99.47% of its industry peers.
OBIO's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for OBIO so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 92.07% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.49%
GM growth 5YN/A
2. Health
2.1 Basic Checks
OBIO does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for OBIO has been increased compared to 1 year ago.
OBIO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
OBIO has an Altman-Z score of -3.22. This is a bad value and indicates that OBIO is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -3.22, OBIO is doing worse than 66.84% of the companies in the same industry.
There is no outstanding debt for OBIO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -3.22 |
ROIC/WACCN/A
WACC8.24%
2.3 Liquidity
OBIO has a Current Ratio of 4.58. This indicates that OBIO is financially healthy and has no problem in meeting its short term obligations.
OBIO's Current ratio of 4.58 is fine compared to the rest of the industry. OBIO outperforms 69.52% of its industry peers.
OBIO has a Quick Ratio of 4.58. This indicates that OBIO is financially healthy and has no problem in meeting its short term obligations.
With a decent Quick ratio value of 4.58, OBIO is doing good in the industry, outperforming 73.80% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.58 | ||
| Quick Ratio | 4.58 |
3. Growth
3.1 Past
The earnings per share for OBIO have decreased strongly by -12.76% in the last year.
Looking at the last year, OBIO shows a very negative growth in Revenue. The Revenue has decreased by -52.07% in the last year.
Measured over the past years, OBIO shows a very negative growth in Revenue. The Revenue has been decreasing by -21.47% on average per year.
EPS 1Y (TTM)-12.76%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-28.57%
Revenue 1Y (TTM)-52.07%
Revenue growth 3Y-21.47%
Revenue growth 5YN/A
Sales Q2Q%-14.97%
3.2 Future
Based on estimates for the next years, OBIO will show a quite strong growth in Earnings Per Share. The EPS will grow by 10.58% on average per year.
The Revenue is expected to grow by 54.92% on average over the next years. This is a very strong growth
EPS Next Y-14.07%
EPS Next 2Y-9.4%
EPS Next 3Y-5.16%
EPS Next 5Y10.58%
Revenue Next Year-16.56%
Revenue Next 2Y32.49%
Revenue Next 3Y-2.51%
Revenue Next 5Y54.92%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
OBIO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year OBIO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A cheap valuation may be justified as OBIO's earnings are expected to decrease with -5.16% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-9.4%
EPS Next 3Y-5.16%
5. Dividend
5.1 Amount
OBIO does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ORCHESTRA BIOMED HOLDINGS IN
NASDAQ:OBIO (9/19/2024, 4:30:02 PM)
After market: 5.3 0 (0%)5.3
+0.41 (+8.38%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap200.45M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -76.79% | ||
| ROE | -125.96% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 92.07% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.03
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 4.58 | ||
| Quick Ratio | 4.58 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-12.76%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y-14.07%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-52.07%
Revenue growth 3Y-21.47%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y